Pricing Log in Create free account

Akari Therapeutics PLC (AKTX) vs Psyence Biomedical Ltd. (PBM)

Akari Therapeutics PLC and Psyence Biomedical Ltd. are both Biotechnology companies. Akari Therapeutics PLC and Psyence Biomedical Ltd. are of similar size ($16.5M and $15.5M). Akari Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Psyence Biomedical Ltd. trades at 0.2×. Across the 10 metrics below, Psyence Biomedical Ltd. leads on 7 and Akari Therapeutics PLC on 3.

Valuation

Metric AKTX PBM Biotechnology median
P/E n/m 0.19 8.50
P/S n/m n/m 9.71
P/B 0.79 0.08 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 1.82 0.64
EV/Sales n/m n/m 9.21
Earnings yield (316.31%) 534.77% (33.15%)
Free cash flow yield (73.67%) (807.70%) (25.50%)

Profitability

Metric AKTX PBM Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (140.09%) (23.52%) (56.36%)
Return on assets (69.16%) (6.74%) (48.04%)
Return on invested capital (167.93%) 0.00% 0.00%

Growth

Metric AKTX PBM Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 68.99% (138.35%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX PBM Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 0.60 8.09 4.72
Net debt to EBITDA 0.27 1.20 0.96

Dividend

Metric AKTX PBM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTX PBM Biotechnology median
Market cap 15.47m 16.47m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack